The company's Q2 2011 earnings call reveals ongoing challenges and a cautious outlook, indicating a potential negative impact on the stock in the short term. Key concerns include a slower-than-expected recovery in the MD&D segment, persistently high unemployment, and healthcare reformsâ€™ effects. The company's decision to exit the drug-eluting stent business also raises questions about future growth prospects. The stock faces further pressure due to the impact of currency fluctuations, an decrease in the amount of product available following the Consent Decree and restructuring efforts. [-2]